和铂医药-B(02142)与辉瑞订立非独家授权协议

Core Viewpoint - The announcement highlights a non-exclusive licensing agreement between Nona Bio, a wholly-owned subsidiary of HAPO (02142), and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Pfizer will gain global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Bio to leverage its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]